GlobeNewswire: EQUASENS Contains the last 10 of 391 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T21:52:14ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/07/2825473/0/fr/EQUASENS-BILAN-SEMESTRIEL-S2-2023-DU-CONTRAT-DE-LIQUIDITE.html?f=22&fvtc=4&fvtv=30562EQUASENS : BILAN SEMESTRIEL S2-2023 DU CONTRAT DE LIQUIDITE2024-02-07T17:30:37Z<![CDATA[Villers-lès-Nancy, le 07 février 2024 - 18h30 (CET)]]>https://www.globenewswire.com/news-release/2024/02/06/2824615/0/en/Equasens-2023-revenue-219-7m-2-6.html?f=22&fvtc=4&fvtv=30562Equasens: 2023 revenue: €219.7m, +2.6%2024-02-06T17:00:00Z<![CDATA[Villers-lès-Nancy, 6 February 2024 - 6:00 p.m. (CET)]]>https://www.globenewswire.com/news-release/2024/02/06/2824615/0/fr/EQUASENS-Chiffre-d-affaires-2023-2-6-%C3%A0-219-7-M.html?f=22&fvtc=4&fvtv=30562EQUASENS : Chiffre d’affaires 2023 : +2,6 % à 219,7 M€2024-02-06T17:00:00Z<![CDATA[Villers-lès-Nancy, le 6 février 2024 - 18h00 (CET)]]>https://www.globenewswire.com/news-release/2024/01/02/2802831/0/en/Equasens-Acquisition-of-a-majority-stake-in-DIGIPHARMACIE.html?f=22&fvtc=4&fvtv=30562Equasens: Acquisition of a majority stake in DIGIPHARMACIE2024-01-02T17:00:00Z<![CDATA[Villers-lès-Nancy, 2 January 2024 - 6:00 p.m. (CET)]]>https://www.globenewswire.com/news-release/2024/01/02/2802831/0/fr/EQUASENS-Prise-de-participation-majoritaire-dans-DIGIPHARMACIE.html?f=22&fvtc=4&fvtv=30562EQUASENS : Prise de participation majoritaire dans DIGIPHARMACIE2024-01-02T17:00:00Z<![CDATA[Villers-lès-Nancy, le 2 janvier 2024 – 18:00 (CET)]]>https://www.globenewswire.com/news-release/2023/12/27/2801459/0/en/Equasens-Changes-in-the-Equasens-Group-Executive-Committee.html?f=22&fvtc=4&fvtv=30562Equasens: Changes in the Equasens Group Executive Committee2023-12-27T17:00:00Z<![CDATA[Villers-lès-Nancy, 27 December 2023 - 6:00 p.m. (CET)PRESS RELEASE]]>https://www.globenewswire.com/news-release/2023/12/27/2801459/0/fr/EQUASENS-Evolution-du-Comit%C3%A9-de-Direction-du-Groupe-Equasens.html?f=22&fvtc=4&fvtv=30562EQUASENS : Evolution du Comité de Direction du Groupe Equasens2023-12-27T17:00:00Z<![CDATA[Villers-lès-Nancy, le 27 décembre 2023 – 18:00 (CET)COMMUNIQUE DE PRESSE]]>https://www.globenewswire.com/news-release/2023/11/23/2785382/0/en/EQUASENS-Acquisition-of-the-German-company-ADV-and-creation-of-PHARMAGEST-Germany.html?f=22&fvtc=4&fvtv=30562EQUASENS: Acquisition of the German company ADV and creation of PHARMAGEST Germany2023-11-23T17:00:00Z<![CDATA[Villers-lès-Nancy, 23 November 2023 - 6:00 p.m. (CET)]]>https://www.globenewswire.com/news-release/2023/11/23/2785382/0/fr/EQUASENS-Acquisition-de-l-allemand-ADV-et-naissance-de-PHARMAGEST-Germany.html?f=22&fvtc=4&fvtv=30562EQUASENS : Acquisition de l’allemand ADV et naissance de PHARMAGEST Germany2023-11-23T17:00:00Z<![CDATA[Villers-lès-Nancy, le 23 novembre 2023 – 18:00 (CET)]]>https://www.globenewswire.com/news-release/2023/11/09/2777646/0/en/Equasens-Q3-2023-revenue.html?f=22&fvtc=4&fvtv=30562Equasens: Q3 2023 revenue2023-11-09T17:00:00Z<![CDATA[Villers-lès-Nancy, 9 November 2023 - 6:00 p.m. (CET)]]>